Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1

Status

Completed 4Terminated 3Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Tumor-Agnostic 2Thoracic 1

Conditions

Prostatic Neoplasms 3Neoplasms 1

Interventions

Docetaxel 69pembrolizumab 48Prednisone 43Nivolumab 40enzalutamide 38Gemcitabine 37Sunitinib 36Cyclophosphamide 29Radiotherapy 26Magnetic Resonance Spectroscopy 26Leuprolide 25Abiraterone Acetate 25Sorafenib 23Everolimus 23Cisplatin 23bicalutamide 19atezolizumab 18Carboplatin 18Bevacizumab 18avelumab 17Radiosurgery 17Goserelin 17Interleukin-2 16abiraterone 15fludarabine 14Doxorubicin 14olaparib 13durvalumab 13cabozantinib 13acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × satraplatin × Genitourinary × Clear all
NCT00450970 2012-08-17

SPERA

Agennix

Phase 3 Terminated
344 enrolled
Genitourinary

Prostatic Neoplasms

NCT00313456 2012-05-10

A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel

Agennix

Phase 1 Terminated
25 enrolled
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT00480623 2012-03-23

A Phase I Trial of Satraplatin Plus Radiation Therapy for Prostate Cancer Patients With Biochemical Recurrence

Agennix

Phase 1 Terminated
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡